STEM-Space™
Unlocking the full potential of our proprietary umbilical cord–derived universal stem cells to deliver a truly scalable, off-the-shelf solution that rapidly meets patient needs.
3 Key Challenges With Current Cell Manufacturing
Unhealthy autologous patient cells yields poor quality of raw source material.
Focusing on cell type doesn’t capture rare cell subtypes affecting desired potency.
Lower rate of cell expansion limits manufacturing scale adding to high costs.
Platform Differentiation
- Begins with healthy cord-derived donor stem cells
- Mimics developmental biology to generate rare, potent cells
- Our novel approach does not require gene editing
- Off-the-shelf solution for rapid delivery within days
- Scalable manufacturing of multiple doses from one cord unit
- Safe, non-invasive and low costs
Mapping the tumor microenvironment by single-cell genomics to reveal specialized population of immune cells amenable to therapeutic intervention.
Vishwakarma et al, Nature Communications Biology (2021)
Disruptive CGT technology assets under management
"We leverage the natural developmental biology of cells for large scale manufacturing. Each cord unit allows 10-100’s of doses per manufacturing run providing unparalleled scalability" - Founder & CEO